Breast Cancer Service
Operational Structure

We are a multi-disciplinary group working together to give non-surgical cancer care to patients with early and advanced breast cancer.

The team includes medical and clinical oncology staff, nurse clinicians, breast care nurse specialists, research nurses, pharmacy staff, physiotherapy and lymphoedema specialists, occupational therapists, research support staff and clinical outcomes staff.

The Christie team of medical and clinical oncologists work with the Greater Manchester and Cheshire breast cancer units who provide diagnostic (radiology and pathology) and surgical services. The aim is to give patients access to clinical care as close to their home as possible. This involves:

- An advice service through working in the weekly breast unit multi-disciplinary meetings
- A clinical consultation service
- Chemotherapy services
- Radiotherapy services
- Links with acute oncology services
- Giving all patients access to relevant clinical trials
- Provision of breast group guidelines, updated annually, to ensure that patients have access to a uniform standard of care, in the units we serve.

Greater Manchester and Cheshire Breast Units Served

Personnel

South Manchester: MDT advice

| Consultants (Medical Oncology) | Dr Andrew Wardley |
| Dr Anne Armstrong |
| Dr Sacha Howell |

| Clinical Oncology | Dr Brian Magee |

Bolton: MDT advice, OP clinics, chemotherapy

| Consultants (Clinical Oncology) | Dr Richard Welch |
| Dr Carmel Anandadas |

Wigan: MDT advice, OP clinics, chemotherapy

| Consultants (Medical Oncology) | Dr Elena Takeuchi |

| Clinical Oncology | Dr Carmel Anandadas |
Pennine Acute (North Manchester General and Oldham): MDT advice, OP clinics, chemotherapy, radiotherapy

**Consultants (Clinical Oncology)**
- Dr Juliette Loncaster
- Dr Vivek Misra
- Dr Helen Lander

Macclesfield: MDT advice, OP clinics, chemotherapy

**Consultants (Clinical Oncology)**
- Dr Lisa Barraclough

Leighton: MDT advice, OP clinics, chemotherapy

**Consultants (Medical Oncology)**
- Dr Laura Horsley

**Clinical Oncology**
- Dr Paul Burt

Stepping Hill: MDT advice, OP clinics, chemotherapy

**Consultants (Clinical Oncology)**
- Dr Abbasi Chittalia

Tameside: MDT advice, OP clinics, chemotherapy

**Consultants (Clinical Oncology)**
- Dr Lubna Bhatt

Salford: MDT advice, OP clinics, chemotherapy, radiotherapy

**Consultants (Medical Oncology)**
- Mr Gregory Wilson

**Clinical Oncology**
- Dr Brian Magee

**Activity**

In 2013/2014 the group saw 2554 patients, mainly referred from the Greater Manchester and Cheshire area.

1137 patients were referred for radiotherapy, 701 patients were referred for chemotherapy

**Service Development 2013/14**

Chemotherapy services are provided at the main Christie site, at a number of the breast cancer units, and via the Christie mobile chemotherapy service. Specialist pharmacy staff (R Duncombe, S Frank, S Stent) advise on systemic therapies and provide chemotherapy services.
Breast Cancer Service

The Christie main site offers a number of outpatient clinics staffed by consultant medical and clinical oncologists, and with specialist grade staff (Y McCabe) and nurse clinicians (B Corke, K Chidlow)

**The adjuvant Herceptin (trastuzumab) service** is a nurse led service (H Mitchell, D Morrissey) that co-ordinates the treatment of patients needing adjuvant Herceptin. Many patients can be treated in their own homes and the team co-ordinates the cardiac assessments needed during treatment.

**The breast care nurse service** (S Foy, R Fox, C Gaskell, B Daniel) provides advice and support to patients referred to the Christie main site. They link with their colleagues in the breast units. The secondary breast cancer pledge is that all patients with newly diagnosed breast cancer have access to specialist breast care nursing advice.

**Psychological medicine advice**: the team works closely with colleagues in psychological medicine (T Hawthorne and others)

**Palliative medicine service**: there is a specific link to the Christie palliative medicine service with staff working in oncology outpatient clinics (T Coleby and others)

**Lymphoedema and re-habilitation services**: patients with lymphoedema, shoulder and arm problems have access to specialist lymphoedema practitioner, physiotherapy and occupational therapy advice (P Williams, J Kenyon, T Eckersley.)

**Radiotherapy services** for breast patients are provided at the Christie main site and the 2 satellite units at Oldham and Salford

**Outcomes – Click Here**
Research

Clinical Trial Activity

The Christie Clinical Trial Research team consistently has broad portfolio of Phase I-III Clinical Trials open at any point in time. We are frequently among the lead UK and International Recruiters in the studies we open. We run 2 dedicated Research Clinics to ensure optimal management of patients on investigational studies.

Trials Currently Open

Pre-Operative

EPHOS-B: Effect of Perioperative AntiHER-2 therapy on Early Breast Cancer Study – Biological phase

Adjuvant

OPTIMA: Personalised Treatment of Breast Cancer

A randomized, Mulitcenter, open-label, Phase III trial comparing Trastuzumab plus Pertuzumab plus a Taxane following Anthracyclines versus trastuzumab emtansine plus Pertuzumab following Anthracyclines as Adjuvant Therapy in Patients with Operable Her-2 Positive Primary Breast Cancer

Persephone: Duration of Trastuzumab with Chemotherapy in Patients with Early Breast Cancer: Six Months versus Twelve

KAITLIN: A randomized, multicenter, Open-label Phase III study to evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with Her2-Positive Primary Breast Cancer who have residual Tumour Present Pathologically in the Breast or Axillary Lymph Nodes Following Pre-Operative Therapy

A study to identify biomarkers which offer a lead interval between predicted relapse and overt disease in post-operative, post-treatment breast cancer patients
Metastatic

ASTELLAS: A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer

BEECH: A Phase I/II, Multicentre, Study Comprising a Safety Run-In of AZD5363 when Combined with Paclitaxel in Patients with Advanced or Metastatic Breast Cancer; Followed by a Randomised Expansion of AZD5363 when Combined with Paclitaxel vs. Paclitaxel plus Placebo in Patients with ER-Positive Advanced or Metastatic Breast Cancer, Stratified by PIK3CA Mutation Status.

BELLE3: A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment

BIOMARIN: A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More than 2 Prior Chemotherapy Regimens for Metastatic Disease

FAKTION: A phase 1b/2 randomised placebo controlled trial of fulvestrant +/- AZD5363 in postmenopausal women with advanced breast cancer previously treated with a third generation aromatase inhibitor.

OLYMPIAD: A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician’s Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with germline BRCA1/2 Mutations

PAKT: A Phase II, randomized, placebo-controlled study of the AKT inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer

TNACITY: A Phase 2/3, Multi-Centre, Open-Label, Randomized study of Weekly nab-Paclitaxel in Combination with Gemcitabine or Carboplatin Compared to Gemcitabine/Carboplatin as First Line Treatment in Subjects with ER, PR and Her2 negative Metastatic Breast Cancer
**Radiotherapy**

IMPORT HIGH: Intensity Modulated and Partial Organ RadioTherapy

**Other**

A study of the barriers to early presentation and diagnosis with breast cancer in black African, black Caribbean and white women

**Other Research Activity**

We have close collaborations with other researchers in the University of Manchester. Dr Armstrong, Dr Howell and Dr Wardley are Principal Investigators within the Manchester Breast Centre which aims to enhance research into breast disease through fostering collaborations across local experts. Dr Armstrong has research interests in immunotherapeutic approaches to breast cancer as well as fertility concerns after a diagnosis of breast cancer. Dr Howell’s laboratory research focus is on endocrine therapy where he is investigating novel antagonists of estrogen and progesterone receptor signalling in pre-clinical models.

**Publications**


**Clinical Audit activity.**

The group undertakes regular audits: e.g. examining the use of growth factors, the use of anti-emetics in patients receiving chemotherapy, the use of newer drugs such as eribulin funded by the national Cancer Drugs Fund, the use of radiotherapy in DCIS.

Data on the morbidity and mortality related to systemic therapy is regularly collected and discussed in team meeting.

**Educational, Teaching and Training Activity.**

The group is involved in education and training of under-graduate and post-graduates in medicine, nursing, radiography and other allied health professionals.